| Title |
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
|
|---|---|
| Published in |
Current Atherosclerosis Reports, September 2016
|
| DOI | 10.1007/s11883-016-0611-4 |
| Pubmed ID | |
| Authors |
Ozlem Bilen, Christie M. Ballantyne |
| Abstract |
Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. Although rodent studies suggested potential effects of ACL inhibition on both fatty acid and cholesterol synthesis, studies in humans show an effect only on cholesterol synthesis. In phase 2 studies, ETC-1002 reduced LDL-C as monotherapy, combined with ezetimibe, and added to statin therapy, with LDL-C lowering most pronounced when ETC-1002 was combined with ezetimibe in patients who cannot tolerate statins. Whether clinically relevant favorable effects on other cardiometabolic risk factors such as hyperglycemia and insulin resistance occur in humans is unknown and requires further investigation. Promising phase 2 results have led to the design of a large phase 3 program to gain more information on efficacy and safety of ETC-1002 in combination with statins and when added to ezetimibe in statin-intolerant patients. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 44% |
| Mexico | 1 | 11% |
| Portugal | 1 | 11% |
| Colombia | 1 | 11% |
| Unknown | 2 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 78% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Unknown | 111 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 12% |
| Student > Ph. D. Student | 12 | 11% |
| Researcher | 11 | 10% |
| Student > Master | 7 | 6% |
| Other | 6 | 5% |
| Other | 18 | 16% |
| Unknown | 45 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 12% |
| Biochemistry, Genetics and Molecular Biology | 10 | 9% |
| Agricultural and Biological Sciences | 8 | 7% |
| Unspecified | 2 | 2% |
| Other | 4 | 4% |
| Unknown | 49 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2023.
All research outputs
#2,601,753
of 23,803,958 outputs
Outputs from Current Atherosclerosis Reports
#144
of 789 outputs
Outputs of similar age
#45,291
of 324,270 outputs
Outputs of similar age from Current Atherosclerosis Reports
#4
of 18 outputs
Altmetric has tracked 23,803,958 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 789 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,270 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.